Euda Health signs MOU with GO POSB Organoids, Shenzhen Inno on iPSC-derived oncology cell therapies
EUDA•Strategic fit for Euda Health
The collaboration supports Euda’s strategy to expand distribution of science-backed wellness and non-invasive healthcare offerings across Asia.
Tri-party MOU on iPSC-derived cell therapies
Euda Health signed a tri-party MOU with GO POSB Organoids and Shenzhen Innovation Immunotechnology to collaborate on iPSC-derived cell therapies.
The parties target development, manufacturing and commercialization of off-the-shelf oncology cell therapies, including iPSC-based NK-TCR programs.
